NASDAQ:AXLAAxcella Health Stock Price, Forecast & News

Axcella Health's stock was trading at $3.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AXLA shares have increased by 80.7% and is now trading at $6.00. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Axcella Health.

Axcella Health is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Axcella Health.

Axcella Health Inc (NASDAQ:AXLA) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.21. View Axcella Health's earnings history.

5 brokerages have issued 12-month price objectives for Axcella Health's shares. Their forecasts range from $10.00 to $28.00. On average, they anticipate Axcella Health's share price to reach $20.60 in the next year. This suggests a possible upside of 243.3% from the stock's current price. View analysts' price targets for Axcella Health.

Media stories about AXLA stock have trended very negative this week, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Axcella Health earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutAxcella Health.

Axcella Health saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 72,100 shares, a decrease of 18.0% from the April 30th total of 87,900 shares. Based on an average daily trading volume, of 70,700 shares, the short-interest ratio is presently 1.0 days. Approximately 0.9% of the shares of the company are sold short. View Axcella Health's Current Options Chain.

Some companies that are related to Axcella Health include Cellectis (CLLS), Avrobio (AVRO), BioCryst Pharmaceuticals (BCRX), Replimune Group (REPL), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), Nantkwest (NK), Osiris Therapeutics (OSIR), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (AVMXY), Vericel (VCEL), Agenus (AGEN), Oyster Point Pharma (OYST), Prevail Therapeutics (PRVL) and Aptose Biosciences (APTO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Coty (COTY), Main Street Capital (MAIN), Myovant Sciences (MYOV), Triton International (TRTN), Carnival (CCL), NVIDIA (NVDA), Occidental Petroleum (OXY), Amarin (AMRN), vTv Therapeutics (VTVT) and Bristol-Myers Squibb (BMY).

(AXLA) raised $76 million in an initial public offering on Thursday, May 9th 2019. The company issued 3,600,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink acted as the underwriters for the IPO.

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Axcella Health's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.48%), State Street Corp (0.50%), JPMorgan Chase & Co. (0.14%), Bank of New York Mellon Corp (0.10%), Chilton Investment Co. LLC (0.07%) and Wells Fargo & Company MN (0.05%). Company insiders that own Axcella Health stock include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet and Ventures Fund Iv LP Flagship. View institutional ownership trends for Axcella Health.

AXLA stock was sold by a variety of institutional investors in the last quarter, including Chilton Investment Co. LLC, and UBS Group AG. View insider buying and selling activity for Axcella Health.

AXLA stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp, and JPMorgan Chase & Co.. Company insiders that have bought Axcella Health stock in the last two years include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet, and Ventures Fund Iv LP Flagship. View insider buying and selling activity for Axcella Health.

Shares of AXLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXLA stock can currently be purchased for approximately $6.00.

Axcella Health has a market capitalization of $205.14 million. The company earns $-59,040,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

The official website for Axcella Health is www.axcellahealth.com.

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-320-2200.